Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Tau PET imaging in neurodegenerative tauopathies-still a challenge
Show others and affiliations
Number of Authors: 72019 (English)In: Molecular Psychiatry, ISSN 1359-4184, E-ISSN 1476-5578, Vol. 24, no 8, p. 1112-1134Article, review/survey (Refereed) Published
Abstract [en]

The accumulation of pathological misfolded tau is a feature common to a collective of neurodegenerative disorders known as tauopathies, of which Alzheimer's disease (AD) is the most common. Related tauopathies include progressive supranuclear palsy (PSP), corticobasal syndrome (CBS), Down's syndrome (DS), Parkinson's disease (PD), and dementia with Lewy bodies (DLB). Investigation of the role of tau pathology in the onset and progression of these disorders is now possible due the recent advent of tau-specific ligands for use with positron emission tomography (PET), including first-(e.g., [F-18] THK5317, [F-18] THK5351, [F-18] AV1451, and [C-11] PBB3) and second-generation compounds [namely [F-18] MK-6240, [F-18] RO-948 (previously referred to as [F-18] RO69558948), [F-18] PI-2620, [F-18] GTP1, [F-18] PM-PBB3, and [F-18] JNJ64349311 ([F-18] JNJ311) and its derivative [F-18] JNJ-067)]. In this review we describe and discuss findings from in vitro and in vivo studies using both initial and new tau ligands, including their relation to biomarkers for amyloid-beta and neurodegeneration, and cognitive findings. Lastly, methodological considerations for the quantification of in vivo ligand binding are addressed, along with potential future applications of tau PET, including therapeutic trials.

Place, publisher, year, edition, pages
2019. Vol. 24, no 8, p. 1112-1134
Keywords [en]
tau, PET, tauopathies, Alzheimer's disease, PSP, CBS, DS, PD, DLB, amyloid-β, neurodegeneration, cognitive findings, in vivo ligand binding
National Category
Neurosciences Neurology Psychiatry
Research subject
Psychology
Identifiers
URN: urn:nbn:se:su:diva-171702DOI: 10.1038/s41380-018-0342-8ISI: 000476715100003PubMedID: 30635637OAI: oai:DiVA.org:su-171702DiVA, id: diva2:1343751
Note

The authors wish to thank the Swedish Foundation for Strategic Research (SSF), the Swedish Research Council (projects 05817, 02695, and 06086), the Regional Agreement on Medical Training and Clinical Research (ALF) for Stockholm County Council, the Foundation for Old Servants, Axel Linder’s Foundation, Gun and Bertil Stohne’s Foundation, the KI Foundations, the Swedish Brain Foundation, the Swedish Alzheimer’s Foundation, Swedish Dementia Association, the Åke Wiberg Foundation, and the EU FW7 large-scale integrating project INMiND (http://www.uni-muenster.de/INMiND) for financial support.

Available from: 2019-08-19 Created: 2019-08-19 Last updated: 2019-12-10Bibliographically approved

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Chiotis, KonstantinosAlmkvist, OveNordberg, Agneta
By organisation
Biological psychology
In the same journal
Molecular Psychiatry
NeurosciencesNeurologyPsychiatry

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 30 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf